High-Intensity Ultrasound Therapy Market to Reach $242 Million by 2033

According to Renub Research Recent Report high-intensity focused ultrasound (HIFU) therapy market is witnessing strong growth, projected to reach $242.58 million by 2033 from $124.44 million in 2024, at a CAGR of 7.7% during 2025–2033. This growth is fueled by increasing adoption of non-invasive treatments, advancements in ultrasound technology, and growing demand for targeted therapies, particularly in oncology, aesthetics, and chronic disease management.

High-intensity ultrasound therapy offers patients a non-invasive alternative to surgery, enabling precise treatment of targeted tissues while minimizing damage to surrounding areas. From prostate cancer to uterine fibroids, HIFU is rapidly becoming a preferred choice in modern healthcare due to shorter recovery times, reduced complications, and enhanced patient comfort.

Understanding High-Intensity Focused Ultrasound (HIFU) Therapy

HIFU therapy works by focusing high-frequency sound waves on specific tissues within the body. The energy generates heat at the targeted point, causing controlled thermal ablation of the tissue without requiring incisions or invasive surgery.

The technology is widely used in oncology to treat localized tumors in organs like the prostate, liver, and pancreas. HIFU also addresses benign conditions, including uterine fibroids and breast tumors, and is increasingly explored for dermatology applications such as facial rejuvenation and skin tightening, stimulating collagen production non-invasively.

The benefits of HIFU—precision targeting, minimal surrounding tissue damage, and shorter recovery periods—position it as a viable alternative to traditional surgical interventions, gaining traction in both hospital and outpatient clinic settings.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Key Growth Drivers in the High-Intensity Ultrasound Therapy Market

Technological Advancements

Innovation in ultrasound systems and imaging technologies has significantly propelled the HIFU market. Advances in real-time monitoring, high-resolution imaging, and treatment precision allow clinicians to identify and treat affected areas with minimal risk to healthy tissue.

In October 2024, GE HealthCare launched the Versana Premier, a versatile, reliable, and cost-effective ultrasound system designed to make advanced imaging more accessible to smaller hospitals and clinics. Similarly, in 2023, GE HealthCare partnered with Novo Nordisk to develop peripheral-focused ultrasound (PFUS) devices, capable of regulating metabolic functions and potentially treating chronic conditions like type 2 diabetes and obesity.

Rising Demand for Non-Invasive Treatments

The increasing preference for minimally invasive healthcare options is a primary driver for HIFU adoption. Patients seek alternatives to traditional surgery for faster recovery, fewer complications, and no anesthesia requirements. HIFU meets these demands by offering treatments for tumors, fibroids, and aesthetic conditions without incisions, making it a patient-preferred option worldwide.

Growth in Chronic Diseases and Cancer

The prevalence of chronic diseases and cancer is surging globally, fueling demand for targeted, non-invasive therapies. In 2022, an estimated 20 million new cancer cases were reported worldwide, along with 9.7 million cancer-related deaths. HIFU therapy provides a solution for localized tumor management, even when surgery is not feasible, with fewer side effects and reduced hospitalization time.

Challenges in the High-Intensity Ultrasound Therapy Market

High Equipment Costs and Limited Accessibility

HIFU requires advanced, specialized ultrasound equipment, which is expensive to purchase and maintain. This limits access, particularly in low-resource regions or smaller healthcare facilities, resulting in unequal treatment availability. Only well-funded hospitals or specialized centers can implement these technologies, posing a significant barrier to widespread adoption.

Shortage of Skilled Professionals

Operating HIFU systems demands highly trained personnel capable of precise targeting and real-time imaging interpretation. A lack of adequately trained technicians can lead to suboptimal treatment outcomes or complications. As the technology evolves, there is a growing need for specialized training programs and clinical education initiatives to ensure safe and effective use of HIFU therapy.

Regional Insights

United States

The U.S. is a leading market for high-intensity ultrasound therapy, driven by technological innovation and patient demand for non-invasive treatments. HIFU is widely used for prostate cancer, uterine fibroids, and other tumors across thousands of medical centers.

The International Agency for Research on Cancer reported 230,125 prostate cancer cases in the U.S. in 2022, with 33,746 deaths. Additionally, the National Cancer Institute (NCI) initiated a Phase 2 clinical trial on prostate cancer using radiation therapy in November 2022, scheduled for completion in 2028, further highlighting ongoing research supporting HIFU adoption.

Germany

Germany is a prominent European market due to advanced healthcare infrastructure and government support for high-tech medical solutions. In June 2023, Exo collaborated with Sana Kliniken AG to deploy a handheld ultrasound platform with AI capabilities, improving real-time decision-making, patient outcomes, and operational efficiency in healthcare settings.

China

China’s HIFU market is growing rapidly, propelled by high prevalence of chronic diseases and rising healthcare investments. Major cities like Beijing and Shanghai are adopting HIFU for cancer treatment and other non-invasive therapies. In February 2023, GE Healthcare formed a joint venture with a Chinese pharmaceutical subsidiary to expand ultrasound solutions and improve accessibility in both urban and rural regions.

Brazil

Brazil is emerging as a key South American market for HIFU therapy, supported by advanced healthcare infrastructure and medical tourism growth. In July 2024, Philips Foundation partnered with SAS Brasil to launch an innovation lab focused on digital health education, aiming to improve healthcare access in remote communities and enhance the adoption of non-invasive treatments like HIFU.

Saudi Arabia

Saudi Arabia is witnessing growth in HIFU therapy adoption due to government investment in healthcare technologies and infrastructure development. Non-invasive treatments, particularly for cancer and uterine fibroids, are gaining traction. In October 2023, Royal Philips showcased healthcare innovations at the Global Health Exhibition, reinforcing Saudi Arabia’s commitment to advanced medical technology adoption.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Sample Report

Market Segmentation

By Imaging Technology

Ultrasound HIFU Therapy

MRI HIFU Therapy

By Application

Prostate Cancer

Uterine Fibroids

Neurological Disorders

Aesthetics

Others

By End-User

Diagnostic Centers

Hospitals

Research Centers

Others

By Region

North America: U.S., Canada

Europe: France, Germany, Italy, Spain, UK, Belgium, Netherlands, Turkey

Asia-Pacific: China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand

Latin America: Brazil, Mexico, Argentina

Middle East & Africa: Saudi Arabia, UAE, South Africa

Key Players in the High-Intensity Ultrasound Therapy Market

Leading companies shaping the global HIFU market include:

Koninklijke Philips N.V.

Johnson & Johnson

Hitachi Ltd.

General Electric (GE) Healthcare

Medtronic Plc.

Stryker

EDAP TMS S.A.

Theraclion

These companies are driving technological innovation, product development, and global expansion, ensuring HIFU remains at the forefront of non-invasive treatment solutions.

The Future of High-Intensity Ultrasound Therapy

High-intensity focused ultrasound therapy is transforming oncology, aesthetics, and chronic disease management by providing precise, non-invasive, and cost-efficient solutions. With technological advancements, rising patient awareness, and expanding healthcare infrastructure, HIFU is poised for sustained global growth through 2033.

From prostate cancer treatments and uterine fibroid management to innovations in AI-guided imaging, the HIFU market continues to evolve. As healthcare systems worldwide seek to minimize invasiveness and improve patient outcomes, high-intensity ultrasound therapy is set to play a pivotal role in the future of medicine.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.